Work

Secosteroid–Isatin Hybrids as Novel Estrogen Receptor α Modulators with Selective Activity Against Hormone-Dependent Breast Cancer

Year: 2026
Type: article
Abstract: Estrogen receptor α (ERα) remains the principal molecular driver of hormone-dependent breast cancer. In this study, we designed, synthesized, and biologically evaluated a new series of secosteroid–isatin hybrids as potential ERα-targeting anticancer agents. The lead compounds, (Z)-3a and (Z)-3b, inhibited MCF-7 cell growth with IC50 values of 6.8 and 6.0 μM, respectively, comparable to cisplatin; they were approximately threefold less potent against epithelial cells than against the target cell model of ERα-positive breast cancer. Mechanistic studies demonstrated that both compounds induced a concentration-dependent depletion of ERα protein, accompanied by downregulation of the ERα-dependent proliferative mediator cyclin D1 and the anti-apoptotic protein Mcl-1, together with accumulation of cleaved PARP, indicating activation of apoptotic cell death. Importantly, an estrogen response element (ERE)-driven luciferase reporter assay demonstrated potent concentration-dependent suppression of 17β-estradiol-induced ERα transcriptional activity, with nearly complete inhibition achieved at higher concentrations, confirming that these compounds function as effective antagonists of ERα-dependent gene transcription. Furthermore, both lead compounds exhibited predominantly synergistic interactions with doxorubicin and heliomycin, suggesting their potential utility in combination therapy. Collectively, these findings identify secosteroid–isatin hybrids as a previously unexplored class of ERα modulators with efficient suppression of estrogen receptor α signaling and induction of apoptosis, which highlights this scaffold as a promising platform for the development of next-generation therapeutics for hormone-dependent breast cancer.
Source: Molecules
Language: English
Subfield: Endocrinology
Open Access status: gold
Estimated APC paid: $3,258
OpenAlex ID: W7225872224
FWCI:
Cites: 129
Cited by:
Related to: 10